Fluorimetric Determination of Antiviral (COVID-19) Drug Favipiravir in Bulk and Pharmaceutical Dosage Forms

  • K. Bhavya Sri Department of Pharmaceutical Analysis, HOD of Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India
  • Md. Saba Fatima Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India
  • Shaheen Banu Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India
  • M. Sumakanth Department of Pharmaceutical Chemistry, Principal at RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

Abstract

Favipiravir is a synthetic prodrug, which was first discovered while assessing the antiviral activity of chemical agents active against the influenza virus in the chemical library of Toyoma chemicals. It works by inhibiting RNA dependant RNA polymerase (RdRP), an enzyme required for RNA viral replication inside human cells. A simple, rapid, and economic method was developed for the quantitative determination of Favipiravirusing spectrofluorometer. The Favipiravir standard drug solution and sample tablet solution was prepared using double distilled water as a diluent. The different concentrations ofpure drugin the range 2-10 μg/ml and one sample solution were measured for the intensity at 432nm in the spectrofluorometer. The calibration curve was plotted and the sample’s unknown concentration was calculated from the plot. The calibration curve was found to be linear with r2 value obtained as 0.99.There are various other methods available for the quantification of Favipiravir which include RP-HPLC, UV-spectroscopic methods, FTIR, LC-MS with different extraction methods spiked in human plasma but not by using spectrofluorometer. Favipiravir shows fluorescence when dissolved in appropriate solvent hencethis method was developed to quantify Favipiravir which is a simple and efficient method. This method developed is easy and can be used for routine quality control test for Favipiravir pharmaceutical formulations.


Keywords: Favipiravir, spectrofluorometer, Calibration curve.

Keywords: Favipiravir, spectrofluorometer, Calibration curve

Downloads

Download data is not yet available.

Author Biographies

K. Bhavya Sri, Department of Pharmaceutical Analysis, HOD of Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

Department of Pharmaceutical Analysis, HOD of Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

Md. Saba Fatima, Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

Shaheen Banu, Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

Department of Pharmaceutical Analysis, RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

M. Sumakanth, Department of Pharmaceutical Chemistry, Principal at RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

Department of Pharmaceutical Chemistry, Principal at RBVRR Women’s College of Pharmacy, Hyderabad, Telangana, India

References

1. Furuta Y, Komeno T, et al., Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, P. Jpn. Acad. B-Phys. 2017; 93:449-463, https://doi.org/10.2183/pjab.93.027
2. Tanaka T, Kamiyama T, et al., T-705 (Favipiravir) suppresses tumor necrosis factor a production in response to influenza virus infection: a beneficial feature of T-705 as an anti-influenza drug, Acta Virol. 2017; 61:48, https://doi.org/10.4149/av_2017_01_48
3. Bai C-Q, Mu J-S, et al., Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, Clin. Infect. Dis. 2014; 63(2016):1288-1294, https://doi.org/10.1093/cid/ciw571
4. Megahed SM, Habib AA, Hammad SF et al, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2021; 249. https://doi.org/10.1016/j.saa.2020.119241
5. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013 Nov; 100:446-454. https://doi.org/10.1016/j.antiviral.2013.09.015
6. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 50 -triphosphate towards influenza A virus polymerase. PloS One. 2013; 8:e68347. https://doi.org/10.1371/journal.pone.0068347
7. Megahed S, Habib A, Hammad S Kamal A, Experimental Design Approach for Development of Spectrofluorimetric Method for Determination of Favipiravir; a Potential Therapeutic Agent against COVID-19 Virus: Application to Spiked Human Plasma. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2020; 249:119241. https://doi.org/10.1016/j.saa.2020.119241
8. 冯光玲丁文娟邓玉晓赵仁永龚艳艳段崇刚孙晋瑞, 2015, A kind of Favipiravir has the HPLC assay method of related substance, CN104914185B.
9. Taşkın D. Development and Validation of a Rapid HPLC-DAD Method for Determination of Favipiravir in Pharmaceutical Formulation. Clinical and Experimental Health Sciences. 2022; 12(3):648-652. https://doi.org/10.33808/clinexphealthsci.992869
10. Hailat M, Al-Ani I, Hamad M, Zakareia Z, Abu Dayyih W. Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma. Molecules 2021; 26:3789. https://doi.org/10.3390/molecules26133789
11. Abdallah IA, Hammad SF, Bedair A, Elshafeey AH, Mansour FR. Determination of favipiravir in human plasma using homogeneous liquid-liquid microextraction followed by HPLC/UV. Bioanalysis. 2022; 14(4):205-216. Epub 2022 Jan 10. PMID: 35001648 https://doi.org/10.4155/bio-2021-0219
12. Onmaz DE, Abusoglu S, Onmaz M, Yerlikaya FH, Unlu A. Development and validation of a sensitive, fast and simple LC-MS/MS method for the quantitation of favipiravir in human serum. Journal of Chromatography B. 2021 Jun 30; 1176:122768. https://doi.org/10.1016/j.jchromb.2021.122768
13. RAGHAVENDRABABU PNN, PADMAVATHI Y, NEENA G, SUSHMA K, POOJITHA A. "NEW FTIR METHOD DEVELOPMENT AND VALIDATION FOR QUANTITATIVE ANALYSIS OF FAVIPIRAVIR IN BULK AND PHARMACEUTICAL DOSAGE FORMS". International Journal of Current Pharmaceutical Research, 2022; 14(5):25-29, doi:10.22159/ijcpr.2022v14i5.2022.
https://doi.org/10.22159/ijcpr.2022v14i5.2022
14. Abdallah, I.A., El-Behairy, M.F., Ahmed, R.M. et al. The anti-COVID-19 drug Favipiravir: Degradation, Method development, Validation, NMR/LC-MS characterization, and In-vitro safety evaluation. Chem. Pap. 2022; 76:6415-6426. https://doi.org/10.1007/s11696-022-02327-5
15. Bulduk İ. Comparison of HPLC and UV Spectrophotometric Methods for Quantification of Favipiravir in Pharmaceutical Formulations. Iran J Pharm Res. 2021; 20(3):57-65. doi: 10.22037/ijpr.2020.114199.14725. PMID: 34903969; PMCID: PMC8653657.
16. El-Awady, M., Elmansi, H., Belal, F. et al. Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir. J Fluoresc 2022; 32:1941-1948. https://doi.org/10.1007/s10895-022-02998-z
17. Ramzy S, Abdelazim AH, Osman AOE, Hasan MA, Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, Volume 2022; 281:121625, ISSN 1386-1425, https://doi.org/10.1016/j.saa.2022.121625
Crossmark
Statistics
268 Views | 32 Downloads
How to Cite
1.
Bhavya Sri K, Fatima MS, Banu S, Sumakanth M. Fluorimetric Determination of Antiviral (COVID-19) Drug Favipiravir in Bulk and Pharmaceutical Dosage Forms. JDDT [Internet]. 15Mar.2023 [cited 19Apr.2024];13(3):110-2. Available from: https://jddtonline.info/index.php/jddt/article/view/5770